FORA Capital’s Immunovant IMVT Stock Holding History

FORA Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,082	Closed	-$502K	–	524
2023 Q3	$502K	Buy	+13,082	New	+$296K	0.04%	335
2021 Q1	–	Sell	-2,395	Closed	-$111K	–	924
2020 Q4	$111K	Buy	+2,395	New	+$111K	0.02%	638

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FORA Capital's IMVT Position: Q4 2023 in Review

FORA Capital sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 13,082 shares — an estimated $502K sold.

FORA Capital first reported a position in IMVT in Q4 2020 and held it in 2 quarters. The position peaked at $502K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

FORA Capital reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
FORA Capital sold 13,082 Immunovant shares in Q4 2023, an estimated $502K.
FORA Capital first reported a position in Immunovant in Q4 2020 and held it in 2 quarters.
FORA Capital's Immunovant position peaked at $502K in Q3 2023.
228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on FORA Capital's 13F filing for Q4 2023, filed 14 Feb 2024.